ASG-15ME and Enfortumab Vedotin (ASG-22ME) Shows Anti-tumor Activity in Patients with Metastatic Urothelial Cancer

First-time clinical data for ASG-15ME and ASG-22ME (Enfortumab vedotin) were presented today at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.

ASG-15ME and ASG-22ME are investigational antibody-drug conjugates (ADCs) consisting of monoclonal antibodies designed to deliver microtubule-disrupting agents selectively to tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity.

ASG-15ME targets SLITRK6 and ASG-22ME targets Nectin-4. These proteins are highly expressed in urothelial cancers, particularly bladder cancer. Under the collaboration, the companies are co-developing and plan to globally co-commercialize ASG-15ME and ASG-22ME.

ASG-15ME is an investigational antibody-drug conjugate (ADC) composed of an anti-SLITRK6 monoclonal antibody attached to a microtubule-disrupting agent, monomethyl auristatin E (MMAE), using Seattle Genetics proprietary, industry-leading linker technology. ASG-15ME is the first and only agent to target SLITRK6, a transmembrane protein identified as an ADC target by Agensys, which is expressed on many solid tumors.

Preclinical data demonstrate that ASG-15ME effectively binds to target cells, internalizes and induces cell-killing activity.

ASG-22ME is an investigational ADC composed of an anti-Nectin-4 monoclonal antibody attached to a microtubule-disrupting agent, Monomethyl-Auristatin E, also known as MMAE, using Seattle Genetics proprietary, industry-leading linker technology. ASG-22ME is the first and only agent to target Nectin-4, a cell adhesion molecule identified as an ADC target by Agensys, which is expressed on many solid tumors. Preclinical data demonstrate that ASG-22ME effectively binds to target cells, internalizes and induces cell-killing activity.

Read the full article on ADC Review / Journal of Antibody-drug Conjugates.


Last editorial review: June 6, 2016. Copyright © 2016 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco'Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Views: 78

Comment

You need to be a member of Onco'Zine to add comments!

Join Onco'Zine

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+